Several studies have reported the efficacy of FLT3 inhibitors combined with MDM2 inhibitors in the treatment of AML [70, 71], suggesting stabilizing p53 leads to more effective treatment. This evidence concerns the gene FLT3 and acute myeloid leukemia.